[Recent advances in the replacement therapy for Hemophilia].
作者信息
Hou P X, Yang R C
机构信息
State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin Key Laboratory of Gene Therapy for Blood Diseases, CAMS Key Laboratory of Gene Therapy for Blood Diseases, Tianjin 300020, China Tianjin Institutes of Health Science, Tianjin 301600, China.
出版信息
Zhonghua Xue Ye Xue Za Zhi. 2023 Dec 14;44(12):1052-1056. doi: 10.3760/cma.j.issn.0253-2727.2023.12.018.
Abstract
摘要
相似文献
1
[Recent advances in the replacement therapy for Hemophilia].
Zhonghua Xue Ye Xue Za Zhi. 2023 Dec 14;44(12):1052-1056. doi: 10.3760/cma.j.issn.0253-2727.2023.12.018.
2
Recent advances in the management of the child who has hemophilia.
Hematol Oncol Clin North Am. 2004 Dec;18(6):1249-76, viii. doi: 10.1016/j.hoc.2004.06.016.
3
[Advances in the field of hemophilia therapy].
Ned Tijdschr Geneeskd. 1968 Sep 7;112(36):1593-5.
4
[Recent advance in hemophilia therapy (2): gene and cell therapy for hemophilia].
Rinsho Ketsueki. 2014 Aug;55(8):899-907.
5
[Hemophilia].
Rinsho Ketsueki. 2013 Feb;54(2):189-97.
6
Status of gene transfer for hemophilia A and B.
Thromb Haemost. 1991 Jul 12;66(1):119-22.
7
Therapy for AHF and PTC hemophilia. I.
IMJ Ill Med J. 1970 May;137(5):518-21.
8
Gene therapy for hemophilia: the clot thickens.
Hum Gene Ther. 2014 Nov;25(11):915-22. doi: 10.1089/hum.2014.2541.
9
A golden age for Haemophilia treatment?
Haemophilia. 2018 Mar;24(2):175-176. doi: 10.1111/hae.13411.
10
[Experiences from the Hemophilia Clinic. II].
Ned Tijdschr Geneeskd. 1968 Jul 27;112(30):1372-7.
引用本文的文献
1
[Chinese guidelines for emergency management of bleeding in hemophilia patients (2024)].
Zhonghua Xue Ye Xue Za Zhi. 2024 Oct 14;45(10):889-896. doi: 10.3760/cma.j.cn121090-20240809-00296.
本文引用的文献
1
Concizumab: First Approval.
Drugs. 2023 Jul;83(11):1053-1059. doi: 10.1007/s40265-023-01912-6.
2
Safety, tolerability, pharmacokinetics and pharmacodynamics of a single dose of marstacimab in Chinese participants with severe haemophilia.
Haemophilia. 2023 Jul;29(4):1155-1159. doi: 10.1111/hae.14814. Epub 2023 Jun 20.
3
Efanesoctocog Alfa: First Approval.
Drugs. 2023 May;83(7):633-638. doi: 10.1007/s40265-023-01866-9.
4
Efficacy and safety of fitusiran prophylaxis in people with haemophilia A or haemophilia B with inhibitors (ATLAS-INH): a multicentre, open-label, randomised phase 3 trial.
Lancet. 2023 Apr 29;401(10386):1427-1437. doi: 10.1016/S0140-6736(23)00284-2. Epub 2023 Mar 29.
5
Fitusiran prophylaxis in people with severe haemophilia A or haemophilia B without inhibitors (ATLAS-A/B): a multicentre, open-label, randomised, phase 3 trial.
Lancet Haematol. 2023 May;10(5):e322-e332. doi: 10.1016/S2352-3026(23)00037-6. Epub 2023 Mar 29.
6
Efanesoctocog Alfa Prophylaxis for Patients with Severe Hemophilia A.
N Engl J Med. 2023 Jan 26;388(4):310-318. doi: 10.1056/NEJMoa2209226.
7
Emicizumab in people with moderate or mild haemophilia A (HAVEN 6): a multicentre, open-label, single-arm, phase 3 study.
Lancet Haematol. 2023 Mar;10(3):e168-e177. doi: 10.1016/S2352-3026(22)00377-5. Epub 2023 Jan 27.
8
Hemorrhagic and thrombotic adverse events associated with emicizumab and extended half-life factor VIII replacement drugs: EudraVigilance data of 2021.
J Thromb Haemost. 2023 Mar;21(3):546-552. doi: 10.1016/j.jtha.2023.01.010. Epub 2023 Jan 16.
9
Long-term safety and efficacy of the anti-tissue factor pathway inhibitor marstacimab in participants with severe haemophilia: Phase II study results.
Br J Haematol. 2023 Jan;200(2):240-248. doi: 10.1111/bjh.18495. Epub 2022 Oct 11.
10
A phase 1b/2 clinical study of marstacimab, targeting human tissue factor pathway inhibitor, in haemophilia.
Br J Haematol. 2023 Jan;200(2):229-239. doi: 10.1111/bjh.18420. Epub 2022 Aug 23.
Zotero 插件